Table 1 Summary of common oncogenic driver mutations, their corresponding testing methods and their respective inhibitors
Target | Detection method | Inhibitor |
|---|---|---|
EGFR | Direct sequencing | Gefitinib, Erlotinib |
Real-time PCR | BIBW2992 (Afatinib) | |
Single-strand conformational polymorphism | PF00299804 (Dacomitinib) | |
High-resolution melting amplicon analysis | HKI-272 (Neratinib) | |
BPI-2009 (Icotinib) | ||
EKB-569 (Pelitinib) | ||
CI-1033 (Canertinib) | ||
GW572016 (Lapatinib) | ||
KRAS | Direct sequencing | Not available |
Real-time PCR | ||
Amplification refractory mutation system (ARMS) | ||
Restriction fragment length polymorphism (RFLP) | ||
Co-amplification at lower denaturation temperature-polymerase chain reaction (COLD-PCR) | ||
ALK Fusion | Fluorescence in situ hybridization (FISH) | PF-02341066 (Crizotinib) |
Immunohistochemistry (IHC) | CH5424802 (AF802) | |
Real-time Reverse Transcription-PCR | ||
MET | Quantitative PCR | PF-02341066 (Crizotinib) |
Fluorescence in situ hybridization (FISH) | ARQ197 (Tivantinib) | |
PCR-based sequencing | GSK1363089 (Foretinib) | |
XL184 (Cabozantinib) | ||
PF-04217903 | ||
| Â | Â | SGX523 |